Incruse Ellipta

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Chronic Obstructive Pulmonary DiseaseHyperhidrosis

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

1

Incruse Ellipta

GGlaxo Dba Glaxosmithkline

Phase 3

62

Veramyst

GSK

Preclinical

263

Flovent

GSK

Preclinical

64

Spiriva

Boehringer Ingelheim

Preclinical

155

Aclidinium Bromide

AstraZeneca

Preclinical

216

Formoterol Fumarate

AstraZeneca

Preclinical

117

Duragesic

CCephalon

Preclinical

28

Narcan

SScienture

Preclinical

19

Zoloft

VViatris Specialty LLC

Preclinical

110

Coumadin

AAbbott

Preclinical

1Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease6 trials

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 4·NCT02236611·1,036 enrolled

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Completed·GSK·Phase 3·NCT02207829·1,017 enrolled

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 3·NCT01822899·717 enrolled

Show 3 more trials

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed·GSK·Phase 3·NCT02164513·10,355 enrolled

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Completed·GSK·Phase 3·NCT02184611·308 enrolled

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn·GSK·Phase 3·NCT02731846

Hyperhidrosis2 trials

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

Completed·GSK·Phase 2·NCT02673619·58 enrolled

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

Completed·GSK·Phase 2·NCT02563899·28 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Completed·GSK·Phase 3·NCT01772134·617 enrolled

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Completed·GSK·Phase 3·NCT01772147·608 enrolled

Unspecified1 trial

Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects

Completed·GSK·Phase 1·NCT01934153·18 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News